We will have limited operations from 15:00 Wednesday 24 December 2025 (AEDT) until Friday 2 January 2026. Find out how to contact us during the holiday period.
AZACIP, AZACITIDINE CA, AZACITIDINE CIPLA (Cipla Australia Pty Ltd)
Product name
AZACIP, AZACITIDINE CA, AZACITIDINE CIPLA
Sponsor
Date registered
Evaluation commenced
Decision date
Approval time
245 working days (255)
Active ingredients
Azacitidine
Registration type
New generic medicine
Indication
AZACIP, AZACITIDINE CA, AZACITIDINE CIPLA (powder for injection) is indicated for the treatment of patients with:
- Intermediate-2 and High-risk Myelodysplastic Syndromes (MDS) according to the International Prognostic Scoring System (IPSS)
- Chronic Myelomonocytic Leukemia [CMMoL (10%-29% marrow blasts without Myeloproliferative Disorder)]
- Acute Myeloid Leukemia (AML) with 20-30% blasts and multi-lineage dysplasia, according to World Health Organisation (WHO), in whom allogenic stem cell transplantation is not indicated